EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Clinical Trials in Prader–Willi Syndrome: A Review

Ranim Mahmoud iD, Virginia Kimonis iD, Merlin G Butler iD

International Journal of Molecular Sciences · 21.01.2023 · 24 (3) · 2150

DOI: 10.3390/ijms24032150 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 21.01.2023. Verfasst von Ranim Mahmoud und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, University of California, Irvine, CA 92697, USA. Hauptthemen laut MEDLINE: Prader-Willi Syndrome, Transcranial Direct Current Stimulation. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of Health (NIH) U54, Prader-Willi Syndrome Association (PWSA)-USA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prader–Willi syndrome (PWS) is a complex, genetic, neurodevelopmental disorder. PWS has three molecular genetic classes. The most common defect is due to a paternal 15q11-q13 deletion observed in about 60% of individuals. This is followed by maternal disomy 15 (both 15 s from the mother), found in approximately 35% of cases. the remaining individuals have a defect of the imprinting center that controls the activity of imprinted genes on chromosome 15. Mild cognitive impairment and behavior problems in PWS include self-injury, anxiety, compulsions, and outbursts in childhood, impacted by genetic subtypes. Food seeking and hyperphagia can lead to morbid obesity and contribute to diabetes and cardiovascular or orthopedic problems. The control of hyperphagia and improving food-related behaviors are the most important unmet needs in PWS and could be addressed with the development of a new therapeutic agent, as currently no approved therapeutics exist for PWS treatment. The status of clinical trials with existing results for the management of obesity and hyperphagia in PWS will be discussed in this review, including treatments such as beloranib, setmelanotide, a diazoxide choline controlled-release tablet (DCCR), an unacylated ghrelin analogue, oxytocin and related compounds, glucagon-like peptide 1 receptor agonists, surgical intervention, and transcranial direct-current stimulation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prader-Willi SyndromeTranscranial Direct Current StimulationFemaleHumansHyperphagiaAnxietyMothers

Stichwörter der Autor:innen

Prader–Willi syndromeclinical trialsgeneticshyperphagiaobesity

Autor:innen und Institutionen

  • Department of Pediatrics, University of California, Irvine, CA 92697, USA.
  • Department of Pediatrics, Faculty of Medicine, Mansoura University, Mansoura, 35516, Egypt.
  • Departments of Neurology and Pathology, University of California, Irvine, CA 92697, USA.
  • Children's Hospital of Orange County, Orange, CA 92868, USA.
  • Departments of Psychiatry & Behavioral Sciences and Pediatrics, University of Kansas Medical Center, Kansas City, KS 66160, USA.

ORCID-Profile: Ranim Mahmoud, Virginia Kimonis, Merlin G Butler

Förderung

  • National Institute of Health (NIH) U54
  • Prader-Willi Syndrome Association (PWSA)-USA

Zitieren

APA

Mahmoud, R., Kimonis, V., & Butler, M. G. (2023). Clinical Trials in Prader–Willi Syndrome: A Review. International Journal of Molecular Sciences, 24(3), 2150. https://doi.org/10.3390/ijms24032150

Vancouver

Mahmoud R, Kimonis V, Butler MG. Clinical Trials in Prader–Willi Syndrome: A Review. International Journal of Molecular Sciences. 2023;24(3):2150. doi:10.3390/ijms24032150

BibTeX
@article{Mahmoud2023,
  author = {Mahmoud, Ranim and Kimonis, Virginia and Butler, Merlin G},
  title = {Clinical Trials in Prader–Willi Syndrome: A Review},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {3},
  pages = {2150},
  doi = {10.3390/ijms24032150}
}
Kostenlos starten →